AU2017365116B2 - Oral compositions comprising beta-escin for reducing acetaldehyde toxicity - Google Patents

Oral compositions comprising beta-escin for reducing acetaldehyde toxicity Download PDF

Info

Publication number
AU2017365116B2
AU2017365116B2 AU2017365116A AU2017365116A AU2017365116B2 AU 2017365116 B2 AU2017365116 B2 AU 2017365116B2 AU 2017365116 A AU2017365116 A AU 2017365116A AU 2017365116 A AU2017365116 A AU 2017365116A AU 2017365116 B2 AU2017365116 B2 AU 2017365116B2
Authority
AU
Australia
Prior art keywords
composition
escin
alcohol
concentration
fruit extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017365116A
Other languages
English (en)
Other versions
AU2017365116A1 (en
Inventor
Katarzyna KOZIAK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Escilab Sp Z Oo
Original Assignee
Escilab Sp Z O O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escilab Sp Z O O filed Critical Escilab Sp Z O O
Publication of AU2017365116A1 publication Critical patent/AU2017365116A1/en
Application granted granted Critical
Publication of AU2017365116B2 publication Critical patent/AU2017365116B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AU2017365116A 2016-11-24 2017-11-24 Oral compositions comprising beta-escin for reducing acetaldehyde toxicity Active AU2017365116B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619846.7A GB201619846D0 (en) 2016-11-24 2016-11-24 Saponin composition
GB1619846.7 2016-11-24
PCT/IB2017/057395 WO2018096502A1 (en) 2016-11-24 2017-11-24 Oral compositions comprising beta-escin for reducing acetaldehyde toxicity

Publications (2)

Publication Number Publication Date
AU2017365116A1 AU2017365116A1 (en) 2019-05-23
AU2017365116B2 true AU2017365116B2 (en) 2023-06-22

Family

ID=58073282

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017365116A Active AU2017365116B2 (en) 2016-11-24 2017-11-24 Oral compositions comprising beta-escin for reducing acetaldehyde toxicity

Country Status (9)

Country Link
US (1) US10799550B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544615B1 (cg-RX-API-DMAC7.html)
JP (1) JP7070933B2 (cg-RX-API-DMAC7.html)
KR (1) KR102569055B1 (cg-RX-API-DMAC7.html)
AU (1) AU2017365116B2 (cg-RX-API-DMAC7.html)
CA (1) CA3044504A1 (cg-RX-API-DMAC7.html)
GB (1) GB201619846D0 (cg-RX-API-DMAC7.html)
PL (2) PL430029A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018096502A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992157T3 (es) * 2018-10-05 2024-12-09 Escilab Sp Z O O Composición oral que comprende b-escina y el uso de la misma
CN116159145B (zh) * 2023-01-31 2025-04-22 四川大学 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076857A1 (en) * 2005-12-30 2007-07-12 Cadbury Holdings Limited Chewing gum composition containing chokeberry

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3533231B2 (ja) * 1993-08-20 2004-05-31 森下仁丹株式会社 アルコール吸収抑制剤
JP4777495B2 (ja) * 1999-04-01 2011-09-21 森下仁丹株式会社 アルコール障害予防剤およびそれを含有する食品
KR101383276B1 (ko) * 2012-03-05 2014-04-08 염장열 아로니아 음료 농축액 및 그 제조방법
KR20140090453A (ko) * 2013-01-09 2014-07-17 (주) 제이비케이자연의학연구소 아로니아 추출물을 함유하는 숙취예방, 숙취해소 또는 간 보호용 조성물
PL405318A1 (pl) * 2013-09-11 2015-03-16 Cezary Bilski Preparat złożony wspomagający odchudzanie na bazie wyciągów roślinnych
KR20160100572A (ko) * 2015-02-16 2016-08-24 학교법인연세대학교 고미가 제거된 남가새 음료 및 이의 제조방법
EP3078381A1 (en) * 2015-04-10 2016-10-12 Warszawski Uniwersytet Medyczny Horse chestnut extract or escins for the treatment of alzheimer's disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007076857A1 (en) * 2005-12-30 2007-07-12 Cadbury Holdings Limited Chewing gum composition containing chokeberry

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Balansky, Inhibition of lung tumor development by berry extracts in mice exposed to cigarette smoke: International journal of cancer, (Nov. 1, 2012) vol. 131, No. 9, pp. 1991-7 (Year: 2012). *
Patlolla, beta-Escin inhibits NNK-induced lung adenocarcinoma and ALDH1A1 and RhoA/Rock expression in A/J mice and growth of H460 human lung cancer cells. Cancer prevention research), (Oct. 2013) vol. 6, No. 10, pp. 1140-9. *
WPI / 2017 Clarivate Analytics Week 201542, 16 March 2015 Derwent World Patents Index; XP002777793, BILSKI C: "Formulation for reducing weight, comprises oral solution containing thickened juice of chokeberry and chestnut and sodium beta-aescin" *

Also Published As

Publication number Publication date
US10799550B2 (en) 2020-10-13
JP7070933B2 (ja) 2022-05-18
JP2019535779A (ja) 2019-12-12
KR20190087437A (ko) 2019-07-24
US20190321432A1 (en) 2019-10-24
KR102569055B1 (ko) 2023-08-21
EP3544615B1 (en) 2022-05-18
PL3544615T3 (pl) 2022-09-19
EP3544615A1 (en) 2019-10-02
CA3044504A1 (en) 2018-05-31
WO2018096502A1 (en) 2018-05-31
AU2017365116A1 (en) 2019-05-23
PL430029A1 (pl) 2021-03-08
GB201619846D0 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
Elnaga et al. Effect of stevia sweetener consumption as non-caloric sweetening on body weight gain and biochemical’s parameters in overweight female rats
Akinyemi et al. Effect of dietary supplementation of ginger and turmeric rhizomes on angiotensin-1 converting enzyme (ACE) and arginase activities in L-NAME induced hypertensive rats
Ramachandran et al. Asiatic acid prevents lipid peroxidation and improves antioxidant status in rats with streptozotocin-induced diabetes
Panza et al. Effects of mate tea consumption on muscle strength and oxidative stress markers after eccentric exercise
US20140194531A1 (en) Hydroxytyrosol benefits mitochondria
US20100004344A1 (en) Anti-oxidant dietary composition containing fruits and vegetables, method for preparing the same and use of the composition
US20120302645A1 (en) Use of hydroxytyrosol for improving muscle differentiation
KR20140090453A (ko) 아로니아 추출물을 함유하는 숙취예방, 숙취해소 또는 간 보호용 조성물
AU2017365116B2 (en) Oral compositions comprising beta-escin for reducing acetaldehyde toxicity
KR20120044807A (ko) 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물
KR101152479B1 (ko) 탈지된 녹차씨 추출물을 유효성분으로 포함하는 항염 또는 항암 조성물
KR19990071183A (ko) 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물
KR20220123272A (ko) 인지 장애 치료용 조성물
KR20090112954A (ko) 항동맥경화 활성을 갖는 몰로키아 추출물을 함유하는 식품
HK40015220A (en) Oral compositions comprising beta-escin and chokeberry juice for reducing acetaldehyde toxicity
HK40015220B (en) Oral compositions comprising beta-escin and chokeberry juice for reducing acetaldehyde toxicity
KR20190061636A (ko) 검은콩 품종 소청자와 소청 2호 추출물을 이용한 항산화용 조성물과 항염증용 조성물
US12364730B2 (en) Composition comprising oil palm phenolics for use in the treatment and prevention of colon diseases and for promoting and maintaining gut and general health
KR101515573B1 (ko) 뉴그린 추출물을 유효성분으로 함유하는 해독용 조성물
US20250090564A1 (en) Bioactives and their uses
EP3357541B1 (en) Methylsulfonylmethane composition for reducing blood alcohol content
KR100450496B1 (ko) 숙취 해소용 음료 조성물
Ferreira et al. Olive Oil and huntington’s disease
KR20030070232A (ko) 오수유 추출물을 함유하는 숙취해소 및 항산화 작용을위한 조성물
EA049244B1 (ru) Функциональный пищевой продукт (варианты)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)